Share on LinkedInShare on LinkedIn

ARTICLE · 07 JUNE 2024

Brussels Regulatory Brief: May 2024

K&L Gates
K&L Gates
Contributor
K&L Gates

K&L Gates

The Firm K&L Gates is an integrated, international law firm. As a single global law firm, truly...

View firm profile
Explore more from K&L Gates

On 12 April 2024, the European Commission (Commission) approved the plan to unwind a transaction in the early cancer detection sector that was implemented before securing clearance...

European UnionAntitrust/Competition Law

Antitrust and Competition

The European Commission Approves Plan to Unwind a Completed Transaction in the Early Cancer Detection Sector

On 12 April 2024, the European Commission (Commission) approved the plan to unwind a transaction in the early cancer detection sector that was implemented before securing clearance and subsequently prohibited in 2022 by the Commission. While the transaction fell below the EU Merger Regulation (EUMR) turnover thresholds, the Commission asserted jurisdiction over the transaction based on a new interpretation under Article 22 of the EUMR, which grants the Commission the power to review transactions below the EU and national filing thresholds. According to the terms agreed with the Commission, the company is exploring several options to divest the target, which is expected to be finalized in the second quarter of 2024.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from